Our blog

Fierce Pharma Asia—A $410M obesity debut; Another Roche ADC deal; Legend, BeiGene as buyout targets?

10th January 2025 Uncategorised 0

A new weight-loss biotech launched with $410 million and three assets from China. Roche’s Chugai penned a deal to develop multi-payload antibody-drug conjugates. Analysts weighed in on whether Legend Biotech and BeiGene could become buyout targets in 2025. And more.

More: Fierce Pharma Asia—A 0M obesity debut; Another Roche ADC deal; Legend, BeiGene as buyout targets?
Source: fierce

FAQ’s

Our Clients

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque sit amet libero magna. Mauris at enim vel nibh scelerisque porttitor id ut leo. Phasellus pretium, leo a lobortis aliquam, nunc tortor pulvinar ipsum, et vulputate lacus tortor a eros. Morbi consequat velit eget augue porttitor vitae molestie diam rutrum.

Management

. Phasellus porta ultrices ante at facilisis. Fusce ornare turpis sit amet lacus egestas elementum. Curabitur risus nunc, consequat ac euismod at, rhoncus in diam. Duis vel rhoncus eros. Phasellus ut neque nec tellus fringilla viverra. Donec pellentesque lectus a quam blandit dictum iaculis mauris ultricies. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Community

Vestibulum ut nunc eu neque mollis accumsan. Fusce est ante, ultrices sed rutrum et, dictum ac nulla. Maecenas posuere bibendum fermentum. Donec iaculis, urna quis pellentesque rhoncus, justo est iaculis diam, pulvinar congue est tellus vel metus. Donec aliquet facilisis sapien. Donec tempor hendrerit purus a dapibus. Praesent aliquet leo ante. Donec non leo lacus, vitae venenatis augue. Vestibulum quam augue, congue a consectetur sed, eleifend a mi.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

Our blog

Fierce Pharma Asia—A $410M obesity debut; Another Roche ADC deal; Legend, BeiGene as buyout targets?

Categories

Lorem ipsum

FAQ’s

Our Clients

Management

Community

Archive

Calendar